Axela Biosciences Inc. was founded in 2024 through the merger of PicoImmune (NanoBiotec) and EmerTher USA, two organizations with over a decade of proven expertise in biopharmaceutical research and innovation. Headquartered in Whippany, New Jersey, Axela was created to bridge the gap between cutting-edge science and real-world therapeutic development, providing partners with the agility and depth needed to accelerate discoveries into impactful medicines.

Our mission is simple: advance drug discovery and development through science, technology, and collaboration. By combining advanced infrastructure with a multidisciplinary team, we help biotech innovators, global pharma, and academic institutions bring precision therapeutics and diagnostics to patients faster.

What sets us apart is our integrated platform of bioassays, biomarker discovery tools, and translational solutions that support every stage of development. From oncology and immunology to inflammation and emerging modalities, we provide the insights needed to move programs forward with confidence. Our infrastructure is built on automation, regulatory-compliant workflows, and multi-omics platforms, enabling data-driven solutions that are both reliable and scalable.

At our core, Axela is more than a CRO. We are a partner in innovation—committed to building lasting collaborations and pushing the boundaries of what’s possible in drug discovery. Together with our clients, we are shaping the future of precision medicine.